Breast cancer surgeons prefer to go it alone

Article

The standard for delivering the best quality of care to breast cancer patients calls for surgeons to consult with other specialists and to provide resources and education to help patients decide their course of treatment. That doesn't mean they do it.

The standard for delivering the best quality of care to breast cancer patients calls for surgeons to consult with other specialists and to provide resources and education to help patients decide their course of treatment.

“But surgeons in the community are reporting relatively little of that,” says Dr. Steven J. Katz, a professor of internal medicine at the University of Michigan Medical School.

Katz and colleagues at the UM Comprehensive Cancer Center asked more than 300 surgeons who treat breast cancer patients in the Detroit and Los Angeles areas about how they conduct their practices. The questions gauged whether the surgeons:

  • consult with medical oncologists, radiation oncologists, and plastic surgeons;

  • collect biopsy specimens or mammograms;

  • offer patient education videos or presentations; and

  • connect patients with peers, for example, through support groups.

Fewer than one-third reported that they routinely discuss patients’ treatment plans with medical or radiation oncologists, according to Katz, who also serves as a professor of health management and policy at the UM School of Public Health. Just 13% reported routinely consulting with a plastic surgeon. About one-third of surgeons said their patients typically participate in patient decision-support activities, such as viewing a video or web-based materials or attending peer support programs.

“Either doctors are not convinced these elements matter or there are logistical constraints in terms of building these standards into their practices,” he said.

The implications for healthcare in the U.S. are substantial. Nearly 200,000 Americans are diagnosed annually with breast cancer each year, according to the American Cancer Society. More than 40,000 die from the disease.

In attending to the needs of this patient population, however, not all surgeons are so cavalier with best practices. Katz noticed that surgeons who treated mostly breast cancer patients were more likely than others to report that they performed services reflecting best practices.

“These results suggest patients might find a more integrated practice among surgeons with higher volume, but we don’t know whether that matters with regards to patient decision-making, quality of life, and satisfaction,” Katz said.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content